Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biomarin Pharmaceutical Inc

NASDAQ: BMRN · Life Sciences · 7 alerts · CIK 1048477

Share price
$57.99Close, Nov 16
Market cap
$11.2B
Shares outstanding
193.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biomarin Pharmaceutical Inc filings on SEC EDGAR ↗

4:34 PM ET 10-Q
Financial Results ▶ Call

Biomarin Pharmaceutical Q3 2026 Results: Net Loss of $123M, Loss Widens

BioMarin reported total revenues of $1.02 billion for the third quarter of 2026, a significant increase from $776.1 million in the prior year, though it recorded a net loss of $122.8 million due to higher operating expenses and intangible asset amortization. The company's balance sheet expanded significantly following a $5.07 billion business combination, funded in part by $3.65 billion in new borrowings.

Key figure
Net loss $123M
4:07 PM ET 8-K
Financial Results

Biomarin Pharmaceutical Financial Results

BioMarin reported third-quarter 2026 financial results, achieving a milestone of over $1 billion in quarterly revenue, a 32% year-over-year increase. Growth was driven by the acquisition of Amicus Therapeutics and strong demand for metabolic and skeletal condition treatments. The company also announced an FDA PDUFA date of May 30, 2027, for the potential expansion of VOXZOGO into hypochondroplasia.

Term
Q3 2026

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”

Alexander Hardy, President and Chief Executive Officer

“As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.”

Alexander Hardy, President and Chief Executive Officer
4:23 PM ET 8-K
Business Update

Biomarin Pharmaceutical Business Update

BioMarin disclosed the estimated financial impact of its August 31, 2026, acquisition of Alesta Therapeutics, including a $283 million pre-tax charge for acquired in-process research and development (IPR&D). The acquisition is expected to have a $1.50 unfavorable impact on Q3 2026 EPS and a $1.55 impact on full-year 2026 EPS, with updated full-year guidance to be provided during the Q3 earnings call.

Counterparty
Alesta Therapeutics B.V.
4:16 PM ET 8-K
Licensing Deal

Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S

BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.

Counterparty
Ascendis Pharma A/S
Term
through May 2030

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.